Cite
HARVARD Citation
Kitagawa, S. et al. (2020). Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review. Thoracic cancer. 11 (7), pp. 1927-1933. [Online].